How to buy Relmada Therapeutics stock | $23.63

Relmada Therapeutics Inc is a biotechnology business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 14 staff and has a market cap (total outstanding shares value) of 0.00.

Relmada Therapeutics stock price (NASDAQ: RLMD)

Use our graph to track the performance of RLMD stocks over time.

Relmada Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-09.

Latest market close	$23.63
52-week range	$20.60 - $40.00
50-day moving average	$25.90
200-day moving average	$30.67
Wall St. target price	$72.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.24

Buy Relmada Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Relmada Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Relmada Therapeutics price performance over time

Historical closes compared with the close of $23.63 from 2021-10-15

1 week (2021-10-08)	-9.71%
1 month (2021-09-17)	-14.26%
3 months (2021-07-16)	-24.19%
6 months (2021-04-16)	-31.88%

1 year (2020-10-16)	-32.21%
2 years (2019-10-16)	2.29%
3 years (2018-10-16)	2,048.18%
5 years (2016-10-14)	2,263.00%

Relmada Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-44.31%
Return on equity TTM	-75.46%
Profit margin	0%
Book value	$5.54
Market capitalisation	$457.3 million

TTM: trailing 12 months

Shorting Relmada Therapeutics shares

There are currently 1.0 million Relmada Therapeutics shares held short by investors – that's known as Relmada Therapeutics's "short interest". This figure is 0.8% down from 1.0 million last month.

There are a few different ways that this level of interest in shorting Relmada Therapeutics shares can be evaluated.

Relmada Therapeutics's "short interest ratio" (SIR)

Relmada Therapeutics's "short interest ratio" (SIR) is the quantity of Relmada Therapeutics shares currently shorted divided by the average quantity of Relmada Therapeutics shares traded daily (recently around 144495.45454545). Relmada Therapeutics's SIR currently stands at 7.04. In other words for every 100,000 Relmada Therapeutics shares traded daily on the market, roughly 7040 shares are currently held short.

However Relmada Therapeutics's short interest can also be evaluated against the total number of Relmada Therapeutics shares, or, against the total number of tradable Relmada Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relmada Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Relmada Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0768% of the tradable shares (for every 100,000 tradable Relmada Therapeutics shares, roughly 77 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Relmada Therapeutics.

Find out more about how you can short Relmada Therapeutics stock.

Relmada Therapeutics share dividends

We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.

Have Relmada Therapeutics's shares ever split?

Relmada Therapeutics's shares were split on a 1:4 basis on 29 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.

Relmada Therapeutics share price volatility

Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $20.6 up to $40. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.2434. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).

Relmada Therapeutics overview

Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York. .

Frequently asked questions

What percentage of Relmada Therapeutics is owned by insiders or institutions?
Currently 2.165% of Relmada Therapeutics shares are held by insiders and 57.508% by institutions. How many people work for Relmada Therapeutics?
Latest data suggests 14 work at Relmada Therapeutics. When does the fiscal year end for Relmada Therapeutics?
Relmada Therapeutics's fiscal year ends in June. Where is Relmada Therapeutics based?
Relmada Therapeutics's address is: 880 Third Avenue, New York, NY, United States, 10022 What is Relmada Therapeutics's ISIN number?
Relmada Therapeutics's international securities identification number is: US75955J4022 What is Relmada Therapeutics's CUSIP number?
Relmada Therapeutics's Committee on Uniform Securities Identification Procedures number is: 134010107